Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 31.07
- Piotroski Score 3.00
- Grade Buy
- Symbol (IMVT)
- Company Immunovant, Inc.
- Price $26.55
- Changes Percentage (1.45%)
- Change $0.38
- Day Low $25.90
- Day High $26.78
- Year High $45.58
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/31/2025
- Fiscal Year End N/A
- Average Stock Price Target $49.00
- High Stock Price Target $57.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.88
- Trailing P/E Ratio -13.39
- Forward P/E Ratio -13.39
- P/E Growth -13.39
- Net Income $-259,336,000
Income Statement
Quarterly
Annual
Latest News of IMVT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?
Despite increased market volatility, experts suggest investing in equities as the market shows signs of economic softness and potential for continued earnings growth. Immunovant, Inc....
By Yahoo! Finance | 1 month ago -
Are Investors Undervaluing Immunovant, Inc. (NASDAQ:IMVT) By 46%?
Immunovant's fair value estimate is 19% higher than its analyst price target. Using a Discounted Cash Flow model, the intrinsic value of the company is calculated at US$8.5b, showing a 46% discount to...
By Yahoo! Finance | 2 months ago
